Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

By sjmartinez • September 10, 2024

Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. PMID: 39252866; PMCID: PMC11381616.

Tags: Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, long COVID, Monoclonal antibodies, outpatient treatment, PASC, Post COVID conditions, Post-acute sequelae of SARS-CoV-2 infection, Publications

Gestational exposure to PM2.5, NO2, and sex steroid hormones: Identifying critical windows of exposure in the Rochester UPSIDE Cohort

Kahwaji M, Duttweiler L, Thurston SW, Harrington D, Miller RK, Murphy SK, Wang C, Brunner J, Ge Y, Lin Y, Hopke PK, O'Connor TG, Zhang[...]

Knowing Your ABCs: Macrophage ABCA1-Mediated Cholesterol Efflux as a Therapeutic Target in Atherosclerotic Cardiovascular Disease

Karpouzas GA, Ronda N. Knowing Your ABCs: Macrophage ABCA1-Mediated Cholesterol Efflux as a Therapeutic Target in Atherosclerotic Cardiovascular Disease. JACC Basic Transl Sci. 2024 Dec[...]

Risk Profile and Prognostic Implications of Premature Advanced Coronary Atherosclerotic Disease Among Young to Early Middle-aged Adults: The Coronary Artery Calcium Consortium

Boakye E, Dehesh M, Dardari Z, Obisesan OH, Osei AD, Dzaye O, Jha K, Rozanski A, Berman DS, Budoff MJ, Miedema MD, Nasir K, Rumberger[...]